CONTENTS

Foreword ................................................................. xix
Preface ................................................................. xxi

Chapter I
Basic Antitrust and Trade Regulation Statutes ................. 1
Sherman Act ................................................................. 1
  Section 1 of the Sherman Act........................................ 1
  Section 2 of the Sherman Act........................................ 1
  Section 3 of the Sherman Act........................................ 1
  Section 4 of the Sherman Act........................................ 2
  Section 5 of the Sherman Act........................................ 2
  Section 6 of the Sherman Act........................................ 3
  Section 6a of the Sherman Act..................................... 3
  Section 7 of the Sherman Act........................................ 3

Clayton Act ................................................................. 4
  Section 1 of the Clayton Act........................................ 4
  Section 2 of the Clayton Act........................................ 5
  Section 3 of the Clayton Act........................................ 7
  Section 4 of the Clayton Act........................................ 7
  Section 4A of the Clayton Act..................................... 9
  Section 4B of the Clayton Act.................................... 10
  Section 4C of the Clayton Act.................................... 10
  Section 4D of the Clayton Act.................................... 12
  Section 4E of the Clayton Act.................................... 12
  Section 4F of the Clayton Act.................................... 12
  Section 4G of the Clayton Act.................................... 13
  Section 4H of the Clayton Act.................................... 13
  Section 5 of the Clayton Act...................................... 13
  Section 6 of the Clayton Act...................................... 18
  Section 7 of the Clayton Act...................................... 18
  Section 8 of the Clayton Act...................................... 19
  Section 11 of the Clayton Act.................................... 21
  Section 12 of the Clayton Act.................................... 26
  Section 13 of the Clayton Act.................................... 26
  Section 14 of the Clayton Act.................................... 26
  Section 15 of the Clayton Act.................................... 27
  Section 16 of the Clayton Act.................................... 27
Robinson-Patman Act (Excerpt) ............................................................. 28
Section 3 of the Robinson-Patman Act ............................................ 28

Federal Trade Commission Act (Excerpts)........................................ 28
Section 5 of the Federal Trade Commission Act.............................. 28
Section 13(b) of the Federal Trade Commission Act ....................... 36
Section 18 of the Federal Trade Commission Act............................ 37
Section 19 of the Federal Trade Commission Act............................ 48

Antitrust Enforcement Enhancements and Cooperation Incentives
Act........................................................................................................... 50
Section 211. Sunset ................................................................. 50
Section 212. Definitions ............................................................ 51
Section 213. Limitation on Recovery ............................................. 52
Section 214. Rights, Authorities, and Liabilities Not Affected........ 53

Chapter II
Statutory Exemptions (Selected) ......................................................... 55
Section 291. Authorization of Associations; Powers ...................... 55
Section 292. Monopolizing or Restraining Trade and Unduly
Enhancing Prices Prohibited; Remedy and Procedure ............... 55

Healthcare Quality Improvement Act ..................................................... 57
Section 11101. Findings ............................................................. 57
Section 11111. Professional Review .................................................. 57

Labor Exemptions ................................................................................... 59
Section 17. Antitrust Laws Not Applicable to Labor
Organizations ................................................................................. 59
Section 52. Statutory Restriction of Injunctive Relief ....................... 60

McCarran-Ferguson Act ................................................................. 60
Section 1011. Declaration of Policy .................................................. 60
Section 1012. Regulation by State Law; Federal Law Relating
Specifically To Insurance; Applicability of
Certain Federal Laws After June 30, 1948 ......................... 61

National Cooperative Research and Production Act of 1993,
as amended by The Standard Setting Development Organization
Section 4301. Definitions ................................................................. 62
Section 4302. Rule of Reason Standard ........................................... 65
Section 4303. Limitation of Recovery .............................................. 66
Section 4304. Award of Costs, Including Attorney’s Fees, To
Substantially Prevailing Party; Offset ........................................... 68
Section 4305. Disclosure of Joint Venture ........................................ 69
Section 4306. Application of Section 4303 Protections to
Production of Products, Processes, and Services ................... 72

Chapter III
2010 Department of Justice and Federal Trade Commission
Horizontal Merger Guidelines .......................................................... 73
1. Overview .................................................................................. 73
2. Evidence of Adverse Competitive Effects ................................. 75
   2.1 Types of Evidence ................................................................. 76
      2.1.1 Actual Effects Observed in Consummated Mergers .... 76
      2.1.2 Direct Comparisons Based on Experience .......... 76
      2.1.3 Market Shares and Concentration in a Relevant
      Market ........................................................................... 76
      2.1.4 Substantial Head-to-Head Competition ................. 77
      2.1.5 Disruptive Role of a Merging Party ...................... 77
   2.2 Sources of Evidence ............................................................... 77
      2.2.1 Merging Parties ............................................................. 77
      2.2.2 Customers ................................................................. 79
      2.2.3 Other Industry Participants and Observers ........... 80
3. Targeted Customers and Price Discrimination .......................... 80
4. Market Definition ....................................................................... 82
   4.1 Product Market Definition ................................................... 84
      4.1.1 The Hypothetical Monopolist Test ......................... 85
      4.1.2 Benchmark Prices and SSNIP Size ....................... 87
      4.1.3 Implementing the Hypothetical Monopolist Test .... 88
      4.1.4 Product Market Definition with Targeted Customers 90
   4.2 Geographic Market Definition .............................................. 91
      4.2.1 Geographic Markets Based on the Locations of
      Suppliers ........................................................................ 92
      4.2.2 Geographic Markets Based on the Locations of
      Customers ....................................................................... 93
5. Market Participants, Market Shares, and Market Concentration .. 95
   5.1 Market Participants ............................................................. 95
   5.2 Market Shares ..................................................................... 97
   5.3 Market Concentration .......................................................... 99
6. Unilateral Effects ................................................................. 101
   6.1 Pricing of Differentiated Products ............................. 102
   6.2 Bargaining and Auctions ............................................. 104
   6.3 Capacity and Output for Homogeneous Products ......... 105
   6.4 Innovation and Product Variety .................................... 106
7. Coordinated Effects ............................................................... 108
   7.1 Impact of Merger on Coordinated Interaction ............. 109
   7.2 Evidence a Market is Vulnerable to Coordinated Conduct ... 110
8. Powerful Buyers ................................................................ 112
9. Entry .................................................................................... 113
   9.1 Timeliness ..................................................................... 114
   9.2 Likelihood ...................................................................... 115
   9.3 Sufficiency ..................................................................... 115
10. Efficiencies ........................................................................ 116
11. Failure and Exiting Assets ..................................................... 119
12. Mergers of Competing Buyers .............................................. 120
13. Partial Acquisitions .............................................................. 121

Chapter IV

2000 Department of Justice and Federal Trade Commission
Antitrust Guidelines for Collaborations Among Competitors ...... 123

Preamble .................................................................................. 123

Section 1: Purpose, Definitions, and Overview ......................... 124
   1.1 Purpose and Definitions .................................. 124
   1.2 Overview of Analytical Framework ....................... 125
   1.3 Competitor Collaborations Distinguished from Mergers ...... 128

Section 2: General Principles for Evaluating Agreements among Competitors ........................................... 129
   2.1 Potential Procompetitive Benefits ............................. 129
   2.2 Potential Anticompetitive Harms ............................... 129
   2.3 Analysis of the Overall Collaboration and the Agreements of Which It Consists ..................... 130
   2.4 Competitive Effects Are Assessed as of the Time of Possible Harm to Competition ................. 130

Section 3: Analytical Framework for Evaluating Agreements among Competitors ......................................... 131
   3.1 Introduction ............................................................... 131
   3.2 Agreements Challenged as Per Se Illegal ....................... 131
   3.3 Agreements Analyzed under the Rule of Reason 133
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.31</td>
<td>Nature of the Relevant Agreement: Business Purpose, Operation in the Marketplace and Possible Competitive Concerns</td>
</tr>
<tr>
<td></td>
<td>3.31(a) Relevant Agreements That Limit Independent Decision Making or Combine Control or Financial Interests</td>
</tr>
<tr>
<td></td>
<td>3.31(b) Relevant Agreements That May Facilitate Collusion</td>
</tr>
<tr>
<td>3.32</td>
<td>Relevant Markets Affected by the Collaboration</td>
</tr>
<tr>
<td></td>
<td>3.32(a) Goods Markets</td>
</tr>
<tr>
<td></td>
<td>3.32(b) Technology Markets</td>
</tr>
<tr>
<td></td>
<td>3.32(c) Research and Development: Innovation Markets</td>
</tr>
<tr>
<td>3.33</td>
<td>Market Shares and Market Concentration</td>
</tr>
<tr>
<td>3.34</td>
<td>Factors Relevant to the Ability and Incentive of the Participants and the Collaboration to Compete</td>
</tr>
<tr>
<td></td>
<td>3.34(a) Exclusivity</td>
</tr>
<tr>
<td></td>
<td>3.34(b) Control over Assets</td>
</tr>
<tr>
<td></td>
<td>3.34(c) Financial Interests in the Collaboration or in Other Participants</td>
</tr>
<tr>
<td></td>
<td>3.34(d) Control of the Collaboration’s Competitively Significant Decision Making</td>
</tr>
<tr>
<td></td>
<td>3.34(e) Likelihood of Anticompetitive Information Sharing</td>
</tr>
<tr>
<td></td>
<td>3.34(f) Duration of the Collaboration</td>
</tr>
<tr>
<td>3.35</td>
<td>Entry</td>
</tr>
<tr>
<td>3.36</td>
<td>Identifying Procompetitive Benefits of the Collaboration</td>
</tr>
<tr>
<td></td>
<td>3.36(a) Cognizable Efficiencies Must Be Verifiable and Potentially Procompetitive</td>
</tr>
<tr>
<td></td>
<td>3.36(b) Reasonable Necessity and Less Restrictive Alternatives</td>
</tr>
<tr>
<td>3.37</td>
<td>Overall Competitive Effect</td>
</tr>
<tr>
<td>Section 4</td>
<td>Antitrust Safety Zones</td>
</tr>
<tr>
<td>4.1</td>
<td>Overview</td>
</tr>
<tr>
<td>4.2</td>
<td>Safety Zone for Competitor Collaborations in General</td>
</tr>
</tbody>
</table>
4.3 Safety Zone for Research and Development
Competition Analyzed in Terms of Innovation
Markets ................................................................. 154
Appendix ................................................................. 155
Section 1.3 ................................................................. 155
Example 1 (Competitor Collaboration/Merger) ........ 155
Section 2.3 ................................................................. 155
Example 2 (Analysis of Individual Agreements/
Set of Agreements) .................................................. 155
Section 2.4 ................................................................. 156
Example 3 (Time of Possible Harm to Competition) . 156
Section 3.2 ................................................................. 157
Example 4 (Agreement not to Compete on Price) ..... 157
Example 5 (Specialization without Integration) ...... 158
Example 6 (Efficiency-Enhancing Integration
Present) ................................................................. 159
Example 7 (Efficiency-Enhancing Integration
Absent) .................................................................... 159
Section 3.3 ................................................................. 160
Example 8 (Rule-of-Reason: Agreement Quickly
Exculpated) ............................................................ 160
Section 3.36(a) ........................................................... 161
Example 9 (Cost Savings from Anticompetitive
Output or Service Reductions) .............................. 161
Example 10 (Efficiencies from Restrictions on
Competitive Independence) ................................. 162

Chapter V
1996 Department of Justice and Federal Trade Commission
Statements of Antitrust Enforcement Policy in Health Care ..... 165
Introduction ............................................................. 165
Physician Network Joint Ventures ................................ 167
Multiprovider Networks ............................................. 167
Safety Zones and Hypothetical Examples ..................... 168
1. Statement of Department of Justice and Federal Trade
Commission Enforcement Policy on Mergers among Hospitals ............................................. 169
Introduction ............................................................. 169
A. Antitrust Safety Zone: Mergers of Hospitals That Will Not Be
Challenged, Absent Extraordinary Circumstances, by the Agencies .............................................. 170
B. The Agencies’ Analysis of Hospital Mergers That Fall outside the Antitrust Safety Zone ............................................ 170

2. Statement of Department of Justice and Federal Trade Commission Enforcement Policy on Hospital Joint Ventures Involving High Technology or Other Expensive Health Care Equipment ...................................................................................... 171
   Introduction .................................................................................... 171
   A. Antitrust Safety Zone: Hospital High Technology Joint Ventures That Will Not Be Challenged, Absent Extraordinary Circumstances, by the Agencies ................................................. 172
   B. The Agencies’ Analysis of Hospital High Technology or Other Expensive Health Care Equipment Joint Ventures That Fall outside the Antitrust Safety Zone .......... 173
   C. Examples of Hospital High Technology Joint Ventures ............. 176
      1. New Equipment That Can Be Offered Only by a Joint Venture .............................................................................. 176
      2. Joint Venture to Purchase Expensive Equipment .............. 176
      3. Joint Venture of Existing Expensive Equipment Where One of the Hospitals in the Venture Already Owns the Equipment ......................................................... 178
      4. Joint Venture of Existing Equipment Where Both Hospitals in the Venture Already Own the Equipment ..... 180

3. Statement of Department of Justice and Federal Trade Commission Enforcement Policy on Hospital Joint Ventures Involving Specialized Clinical or Other Expensive Health Care Services .................................................................................. 183
   Introduction .................................................................................... 183
   A. The Agencies’ Analysis of Hospital Joint Ventures Involving Specialized Clinical or Other Expensive Health Care Services .............................................................. 184
   B. Example—Hospital Joint Venture for New Specialized Clinical Service Not Involving Purchase of High Technology or Other Expensive Health Care Equipment ....... 186

   Introduction .................................................................................... 188
   A. Antitrust Safety Zone: Providers’ Collective Provision of Non Fee Related Information That Will Not Be Challenged, Absent Extraordinary Circumstances, by the Agencies........ 189
5. Statement of Department of Justice and Federal Trade Commission Enforcement Policy on Providers’ Collective Provision of Fee Related Information to Purchasers of Health Care Services................................................................. 190
   Introduction .................................................................................... 190
   A. Antitrust Safety Zone: Providers’ Collective Provision of Fee-Related Information That Will Not Be Challenged, Absent Extraordinary Circumstances, by the Agencies .......... 191
   B. The Agencies’ Analysis of Providers’ Collective Provision of Fee-Related Information That Falls outside the Antitrust Safety Zone ..................................................................................................................... 192

   Introduction .................................................................................... 194
   A. Antitrust Safety Zone: Exchanges of Price and Cost Information Among Providers That Will Not Be Challenged, Absent Extraordinary Circumstances, by the Agencies ................................................................. 194
   B. The Agencies’ Analysis of Provider Exchanges of Information That Fall outside the Antitrust Safety Zone ............................................................... 195

7. Statement of Department of Justice and Federal Trade Commission Enforcement Policy on Joint Purchasing Arrangements among Health Care Providers ................................................. 196
   Introduction .................................................................................... 196
   A. Antitrust Safety Zone: Joint Purchasing Arrangements among Health Care Providers That Will Not Be Challenged, Absent Extraordinary Circumstances, by the Agencies ...... 197
   B. Factors Mitigating Competitive Concerns with Joint Purchasing Arrangements That Fall outside the Antitrust Safety Zone ............................................................................................................................ 199
   C. Example—Joint Purchasing Arrangement Involving Both Hospitals in Rural Community That the Agencies Would Not Challenge ................................................................. 200
      Competitive Analysis ........................................................................... 200

   Introduction .................................................................................... 201
   A. Antitrust Safety Zones ........................................................................ 203
CONTENTS

1. Exclusive Physician Network Joint Ventures That the Agencies Will Not Challenge, Absent Extraordinary Circumstances ................................................................. 204
2. Non Exclusive Physician Network Joint Ventures That the Agencies Will Not Challenge, Absent Extraordinary Circumstances ................................................................. 204
3. Indicia of Non Exclusivity ................................................................. 205

B. The Agencies’ Analysis of Physician Network Joint Ventures That Fall outside the Antitrust Safety Zones ................. 208
1. Determining When Agreements among Physicians in a Physician Network Joint Venture Are Analyzed under the Rule of Reason ................................................................. 209
2. Applying the Rule of Reason ............................................................... 211

C. Examples of Physician Network Joint Ventures ........................................ 215
1. Physician Network Joint Venture Involving Clinical Integration ........................................................................................................ 216
   Competitive Analysis ........................................................................ 217
2. Physician Network Joint Venture Involving Risk Sharing and Non Risk Sharing Contracts ............................................................. 219
   Competitive Analysis ........................................................................ 219
3. Physician Network That Is Per Se Unlawful ........................................... 220
   Competitive Analysis ........................................................................ 221
4. Exclusive Physician Network Joint Venture with Financial Risk Sharing and Comprising More Than Twenty Percent of Physicians with Active Admitting Privileges at a Hospital ....................................................... 221
   Competitive Analysis ........................................................................ 223
5. Physician Network Joint Venture with Financial Risk Sharing and a Large Percentage of Physicians in a Relatively Small Community ................................................................. 223
   Competitive Analysis ........................................................................ 225
6. Physician Network Joint Venture with Financial Risk Sharing and a Large Percentage of Physicians in a Small, Rural County ................................................................. 226
   Competitive Analysis ........................................................................ 227
7. Physician Network Joint Venture with No Price Agreement and Involving All of the Physicians in a Small, Rural County ................................................................. 228
   Competitive Analysis ........................................................................ 229

   Introduction .................................................................................... 230
   A. Determining When Agreements among Providers in a Multiprovider Network Are Analyzed under the Rule of Reason ................................................................. 231
   B. Applying the Rule of Reason ................................................... 235
      1. Market Definition .............................................................. 236
      2. Competitive Effects ........................................................ 237
         a. Horizontal Analysis .................................................... 237
         b. Vertical Analysis ........................................................ 239
         c. Exclusion of Particular Providers ............................... 241
      3. Efficiencies ........................................................................ 242
      4. Information Used in the Analysis.................................... 243
   C. Arrangements That Do Not Involve Horizontal Agreements on Prices or Price Related Terms ...................................................... 243
   D. Examples of Multiprovider Network Joint Ventures ............... 245
      1. PHO Involving Substantial Clinical Integration................ 245
         Competitive Analysis ........................................................ 247
      2. PHO That Provides Services on a Per Case Basis ............. 248
         Competitive Analysis ..................................................... 249
      3. PHO with All the Physicians in a Small, Rural County .... 249
         Competitive Analysis ..................................................... 250
      4. PHO That Does Not Involve Horizontal Agreements on Price .................................................................. 251
         Competitive Analysis ..................................................... 253

Chapter VI
1995 Department of Justice and Federal Trade Commission
Antitrust Guidelines for the Licensing of Intellectual Property ..... 255

   1. Intellectual Property Protection and the Antitrust Laws ....... 255
   2. General Principles .............................................................. 257
      2.1 Standard Antitrust Analysis Applies to Intellectual Property .. 257
      2.2 Intellectual Property and Market Power .......................... 258
      2.3 Procompetitive Benefits of Licensing ............................. 259
   3. Antitrust Concerns and Modes of Analysis ............................ 261
      3.1 Nature of the Concerns ..................................................... 261
      3.2 Markets Affected by Licensing Arrangements ............... 262
         3.2.1 Goods Markets ....................................................... 263
         3.2.2 Technology Markets ................................................ 263
         3.2.3 Research and Development: Innovation Markets....... 266
CONTENTS

3.3 Horizontal and Vertical Relationships ........................................... 270
3.4 Framework for Evaluating Licensing Restraints ............................ 273
4. General Principles Concerning the Agencies’ Evaluation of Licensing Arrangements under the Rule of Reason ............................... 276
4.1 Analysis of Anticompetitive Effects ............................................. 276
   4.1.1 Market Structure, Coordination, and Foreclosure ................... 276
   4.1.2 Licensing Arrangements Involving Exclusivity ....................... 277
4.2 Efficiencies and Justifications ..................................................... 279
4.3 Antitrust “Safety Zone” .............................................................. 281
5. Application of General Principles ................................................. 282
   5.1 Horizontal Restraints ............................................................. 283
   5.2 Resale Price Maintenance ...................................................... 284
   5.3 Tying Arrangements ............................................................ 285
   5.4 Exclusive Dealing ............................................................... 286
   5.5 Cross-Licensing and Pooling Arrangements ............................ 287
   5.6 Grantbacks ....................................................................... 289
   5.7 Acquisition of Intellectual Property Rights ............................ 290
6. Enforcement of Invalid Intellectual Property Rights ...................... 292

Chapter VII

1995 Department of Justice and Federal Trade Commission Antitrust Enforcement Guidelines for International Operations ... 293
1. Introduction .................................................................................. 293
2. Antitrust Laws Enforced by the Agencies ...................................... 294
   2.1 Sherman Act ........................................................................ 295
   2.2 Clayton Act ........................................................................ 296
   2.3 Federal Trade Commission Act ............................................. 297
   2.4 Hart-Scott-Rodino Antitrust Improvements
      Act of 1976 ........................................................................ 297
   2.5 National Cooperative Research and Production Act ............... 299
   2.6 Webb-Pomerene Act ........................................................... 300
   2.7 Export Trading Company Act of 1982 .................................. 300
   2.8 Other Pertinent Legislation ................................................... 303
      2.81 Wilson Tariff Act.............................................................. 303
      2.82 Antidumping Act of 1916 ................................................. 303
      2.83 Tariff Act of 1930 .......................................................... 303
         2.831 Countervailing Duties ................................................. 304
         2.832 Antidumping Duties .................................................. 304
         2.833 Section 337 .............................................................. 304
      2.84 Trade Act of 1974 .......................................................... 305
         2.841 Section 201 ............................................................... 305
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.842</td>
<td>Section 301</td>
<td>305</td>
</tr>
<tr>
<td>2.9</td>
<td>Relevant International Agreements</td>
<td>306</td>
</tr>
<tr>
<td>2.91</td>
<td>Bilateral Cooperation Agreements</td>
<td>306</td>
</tr>
<tr>
<td>2.92</td>
<td>International Guidelines and Recommendations</td>
<td>307</td>
</tr>
<tr>
<td>3.</td>
<td>Threshold International Enforcement Issues</td>
<td>308</td>
</tr>
<tr>
<td>3.1</td>
<td>Jurisdiction</td>
<td>308</td>
</tr>
<tr>
<td>3.11</td>
<td>Jurisdiction over Conduct Involving Import Commerce</td>
<td>309</td>
</tr>
<tr>
<td>3.12</td>
<td>Jurisdiction over Conduct Involving Other Foreign Commerce</td>
<td>310</td>
</tr>
<tr>
<td>3.121</td>
<td>Jurisdiction in Cases under Subsection 1(A) of the FTAIA</td>
<td>310</td>
</tr>
<tr>
<td>3.122</td>
<td>Jurisdiction in Cases under Subsection 1(B) of the FTAIA</td>
<td>313</td>
</tr>
<tr>
<td>3.13</td>
<td>Jurisdiction When U.S. Government Finances or Purchases</td>
<td>316</td>
</tr>
<tr>
<td>3.14</td>
<td>Jurisdiction under Section 7 of the Clayton Act</td>
<td>318</td>
</tr>
<tr>
<td>3.2</td>
<td>Comity</td>
<td>319</td>
</tr>
<tr>
<td>3.3</td>
<td>Effects of Foreign Government Involvement</td>
<td>323</td>
</tr>
<tr>
<td>3.31</td>
<td>Foreign Sovereign Immunity</td>
<td>323</td>
</tr>
<tr>
<td>3.32</td>
<td>Foreign Sovereign Compulsion</td>
<td>325</td>
</tr>
<tr>
<td>3.33</td>
<td>Acts of State</td>
<td>328</td>
</tr>
<tr>
<td>3.34</td>
<td>Petitioning of Sovereigns</td>
<td>329</td>
</tr>
<tr>
<td>3.4</td>
<td>Antitrust Enforcement and International Trade Regulation</td>
<td>330</td>
</tr>
<tr>
<td>4.</td>
<td>Personal Jurisdiction and Procedural Rules</td>
<td>332</td>
</tr>
<tr>
<td>4.1</td>
<td>Personal Jurisdiction and Venue</td>
<td>332</td>
</tr>
<tr>
<td>4.2</td>
<td>Investigatory Practice Relating to Foreign Nations</td>
<td>333</td>
</tr>
<tr>
<td>4.22</td>
<td>Hart-Scott-Rodino: Special Foreign Commerce Rules</td>
<td>334</td>
</tr>
</tbody>
</table>

Chapter VIII

1984 Department of Justice Merger Guidelines (Excerpts)

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Purpose and Underlying Policy Assumptions</td>
<td>337</td>
</tr>
<tr>
<td>4.</td>
<td>Horizontal Effect from Non-Horizontal Mergers</td>
<td>339</td>
</tr>
<tr>
<td>4.2</td>
<td>Competitive Problems from Vertical Mergers</td>
<td>339</td>
</tr>
<tr>
<td>4.21</td>
<td>Barriers to Entry from Vertical Mergers</td>
<td>339</td>
</tr>
<tr>
<td>4.211</td>
<td>Need for Two-Level Entry</td>
<td>339</td>
</tr>
<tr>
<td>4.212</td>
<td>Increased Difficulty of Simultaneous Entry of Both Markets</td>
<td>340</td>
</tr>
<tr>
<td>4.213</td>
<td>Structure and Performance of the Primary Market</td>
<td>341</td>
</tr>
</tbody>
</table>
CONTENTS xv

4.22 Facilitating Collusion through Vertical Mergers ............. 342
  4.221 Vertical Integration to the Retail Level .................. 342
  4.222 Elimination of a Disruptive Buyer ......................... 342
  4.23 Evasion of Rate Regulation ............................................. 343
  4.24 Efficiencies .......................................................... 343

Chapter IX
Guides for Advertising Allowances and Other Merchandising Payments and Services (Fred Meyer Guides) ................................... 345
  Section 240.1 Purpose of the Guides. ................................. 345
  Section 240.2 Applicability of the law ................................ 345
  Section 240.3 Definition of seller. ..................................... 346
  Section 240.4 Definition of customer. ................................ 346
  Section 240.5 Definition of competing customers .................. 347
  Section 240.6 Interstate commerce .................................... 348
  Section 240.7 Services or facilities .................................... 348
  Section 240.8 Need for a plan ............................................. 349
  Section 240.9 Proportionally equal terms .......................... 349
  Section 240.10 Availability to all competing customers ........... 351
  Section 240.11 Wholesaler or third party performance of
    seller’s obligations................................................ 354
  Section 240.12 Checking customer’s use of payments ............. 354
  Section 240.13 Customer’s and third party liability ................ 355
  Section 240.14 Meeting competition ................................... 357
  Section 240.15 Cost justification ....................................... 357

Chapter X
Hart-Scott-Rodino Act .......................................................... 359
  Section 7A of the Clayton Act ........................................... 359

Chapter XI
Hart-Scott-Rodino Regulations ............................................. 369
  Part 801—Coverage Rules ................................................... 369
  Section 801.1 Definitions ................................................ 369
  Section 801.2 Acquiring and acquired persons ..................... 384
  Section 801.3 Activities in or affecting commerce ................. 388
  Section 801.4 Secondary acquisitions ................................ 388
  Section 801.10 Value of voting securities, non-corporate
    interests and assets to be acquired................................... 390
  Section 801.11 Annual net sales and total assets .................. 393
  Section 801.12 Calculating percentage of voting securities .... 396
Section 801.13 Aggregation of voting securities, assets and non-corporate interests. ........................................... 399
Section 801.14 Aggregate total amount of voting securities and assets.................................................................. 403
Section 801.15 Aggregation of voting securities, non-corporate interests and assets the acquisition of which was exempt.................................................. 404
Section 801.20 Acquisitions subsequent to exceeding threshold.. 409
Section 801.21 Securities and cash not considered assets when acquired. ......................................................... 409
Section 801.30 Tender offers and acquisitions of voting securities from third parties. .............................................. 410
Section 801.31 Acquisitions of voting securities by offerees in tender offers. ...................................................... 412
Section 801.32 Conversion and acquisition. ................................................................. 414
Section 801.33 Consummation of an acquisition by acceptance of tendered shares of payment. .......... 414
Section 801.40 Formation of joint venture or other corporations. .......................................................... 414
Section 801.50 Formation of unincorporated entities. .......................................................... 417
Section 801.90 Transactions or devices for avoidance. .......................................................... 418

Part 802 – Exemption Rules ................................................................. 420
Section 802.1 Acquisitions of goods and realty in the ordinary course of business.................. 420
Section 802.2 Certain acquisitions of real property assets.............. 425
Section 802.3 Acquisitions of carbon-based mineral reserves.... 433
Section 802.4 Acquisitions of voting securities of issuers or non-corporate interests in unincorporated entities holding certain assets the acquisition of which is exempt. .............................................. 435
Section 802.5 Acquisitions of investment rental property assets. ........................................................ 437
Section 802.6 Federal agency approval.......................................................... 438
Section 802.8 Certain supervisory acquisitions. .................. 439
Section 802.9 Acquisition solely for the purpose of investment. .......................................................... 440
Section 802.10 Stock dividends and splits; reorganizations. ........ 440
Section 802.21 Acquisitions of voting securities not meeting or exceeding greater notification threshold (as adjusted). .......................................................... 442
| Section 802.23 | Amended or renewed tender offers. | 444 |
| Section 802.30 | Intraperson transactions. | 446 |
| Section 802.31 | Acquisitions of convertible voting securities. | 448 |
| Section 802.35 | Acquisitions by employee trusts. | 448 |
| Section 802.40 | Exempt formation of corporations or unincorporated entities. | 449 |
| Section 802.41 | Corporations or unincorporated entities at time of formation | 449 |
| Section 802.42 | Partial exemption for acquisitions in connection with the formation of certain joint ventures or other corporations | 450 |
| Section 802.50 | Acquisitions of foreign assets. | 450 |
| Section 802.51 | Acquisitions of voting securities of a foreign issuer. | 452 |
| Section 802.52 | Acquisitions by or from foreign governmental entities. | 454 |
| Section 802.53 | Certain foreign banking transactions. | 455 |
| Section 802.60 | Acquisitions by securities underwriters. | 455 |
| Section 802.63 | Certain acquisitions by creditors and insurers. | 455 |
| Section 802.64 | Acquisitions of voting securities by certain institutional investors. | 456 |
| Section 802.65 | Exempt acquisition of non-corporate interests in financing transactions. | 459 |
| Section 802.70 | Acquisitions subject to order. | 459 |
| Section 802.71 | Acquisitions by gift, intestate succession or devise, or by irrevocable trust. | 460 |
| Section 802.80 | Transitional rule for transactions investigated by the agencies. | 460 |

**Part 803—Transmittal Rules** | 460 |
| Section 803.1 | Notification and Report Form. | 460 |
| Section 803.2 | Instructions applicable to Notification and Report Form. | 461 |
| Section 803.3 | Statement of reasons for noncompliance. | 464 |
| Section 803.4 | Foreign persons refusing to file notification. | 464 |
| Section 803.5 | Affidavits required. | 465 |
| Section 803.6 | Certification. | 468 |
| Section 803.7 | Expiration of notification. | 469 |
| Section 803.8 | Foreign language documents. | 470 |
| Section 803.9 | Filing fee. | 470 |
| Section 803.10 | Running of time. | 475 |
Section 803.11 Termination of waiting period.......................... 478
Section 803.20 Requests for additional information or
documentary material........................................... 479
Section 803.21 Additional information shall be supplied
within reasonable time. ......................................... 483
Section 803.30 Formal and informal interpretations of
requirements under the Act and the rules........... 483
Section 803.90 Separability. .................................................. 484